In patients with diabetic macular edema, combination treatment with nesvacumab and aflibercept had no visual benefit over aflibercept alone, according to data from the phase 2 RUBY study published in Retina.
Some patients with DME do not completely respond to standard treatment with aflibercept or ranibizumab. Meanwhile, patients with diabetes have demonstrated increased intravitreal and plasmas levels of angiopoietin-2 (Ang2), making nesvacumab, an Ang2 inhibitor, a potential treatment for DME.
In the study, 302 eyes were randomly assigned 1:2:3 to nesvacumab 3 mg plus aflibercept 2 mg,